Abstract
Chronic joint pain represents a high-prevalence disabling condition with an unmet need for effective treatment. Recent advances in our understanding of the molecular basis of the inhibitory effects of botulinum toxin on neuronal exocytosis, as well as the neurobiology of persistent osteoarticular pain, are emerging with preclinical animal studies and initial clinical experience with intra-articular administration of botulinum toxin type A. The convergence of notable progress in these basic and clinical science investigations presents a sound and attractive foundation for a timely discussion of interactive translation of basic research findings into clinical experience and back again to the laboratory.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
